← Back to Calendar

elebsiran

Alnylam / Roche · $ALNY
Priority Review Breakthrough Therapy NDA
PDUFA Date
November 10, 2026
Time Remaining
231 days
Review Type
Priority (6 mo)
90%
Baseline PoA
Historical NDA
approval rate
Dynamic PoA
Coming soon
xAI Sentiment

Indication

Hepatitis B virus (HBV) — functional cure combination therapy

Key Notes

RNAi therapy in combination with imdusiran targeting functional cure for chronic HBV.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.
← Back to Full Calendar
Advertisement